Skip to content
Clinical Trials for Alzheimer's Disease

Tampa, Florida

Alzheimer's disease clinical trials in Tampa, FL

20 Alzheimer's disease studies are recruiting participants at sites in Tampa as of November 16, 2026, according to ClinicalTrials.gov. Clinical Trials for Alzheimer's Disease can help you understand your options and connect with a study team.

Call (888) 927-5895
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Tampa at a glance

  • 20 studies are recruiting at a site in Tampa.
  • By phase: Phase 1 (1), Phase 2 (7), Phase 3 (8), No phase (2), Observational (2). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (17), university, hospital or other (3).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Tampa

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

    • Phase 3
    • Ages 50 to 90
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Axiom Brain Health LLC
    Registry record
    NCT07177352 · updated
  2. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study sites
    Angels Clinical Research Institute Tampa - Palm Springs - PPDS · Guardian Angel Research · Interventional Psychiatry of Tampa Bay
    Registry record
    NCT05980949 · updated
  3. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  4. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    IPTB Clinical Research
    Registry record
    NCT06937229 · updated
  5. A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Sanofi
    Study site
    Axiom Brain Health- Site Number : 8400019
    Registry record
    NCT07688213 · updated
  6. A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Axiom Brain Health LLC
    Registry record
    NCT07589595 · updated
  7. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study site
    University of South Florida
    Registry record
    NCT06540833 · updated
  8. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study sites
    Psych Me Medical Research Inc · Quantum Research Associates Corp
    Registry record
    NCT06651567 · updated
  9. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    IPTB Clinical Research
    Registry record
    NCT07011745 · updated
  10. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    • Phase 3
    • Ages 55 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study sites
    Care Access - Tampa · K2 Medical Research - Tampa
    Registry record
    NCT07602582 · updated
  11. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study sites
    Guardian Angel Research · Interventional Psychiatry of Tampa Bay
    Registry record
    NCT06585787 · updated
  12. A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

    • Phase 2
    • Ages 50 to 85
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Axiom Brain Health ( Site 1029) · K2 Medical Research ( Site 1020)
    Registry record
    NCT07033494 · updated
  13. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

    • Phase 3
    • Ages 60 to 85
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    USF Health Byrd Alzheimer's Institute
    Registry record
    NCT06976203 · updated
  14. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    Celgene
    Study site
    University of South Florida, Department of Psychiatry and Behavioral Neurosciences
    Registry record
    NCT06808984 · updated
  15. Microbiome in Aging of Gut and Brain

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    University of South Florida
    Study site
    Department of Neurosurgery and Brain and Spine and Faculty of USF Center for Microbiome Re-search, Microbiomes Institute
    Registry record
    NCT07799402 · updated
  16. AV-1980R (Tau Vaccine) in Preclinical Alzheimer's Disease (TAURUS-1980)

    • Phase 1
    • Ages 65 to 80
    • All sexes
    Sponsor
    Institute for Molecular Medicine
    Study site
    University of South Florida
    Registry record
    NCT07158905 · updated
  17. A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    University of South Florida
    Registry record
    NCT05511363 · updated
  18. Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP)

    • No phase
    • Ages 21 and older
    • All sexes
    Sponsor
    University of South Florida
    Study site
    University of South Florida
    Registry record
    NCT06722352 · updated
  19. Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

    • Observational
    • Ages 60 to 90
    • All sexes
    Sponsor
    GAP Innovations, PBC
    Study site
    Axiom Brain Health
    Registry record
    NCT06584357 · updated
  20. ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

    • No phase
    • Ages 50 to 85
    • All sexes
    Sponsor
    InSightec
    Study site
    Tampa General Hospital
    Registry record
    NCT03671889 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Tampa, FL on ClinicalTrials.gov.

Ask about studies near Tampa

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5895

or send a short form

How should we reach you?

Call